Bfsg LLC Has $4.68 Million Holdings in Pfizer Inc. (NYSE:PFE)

Bfsg LLC raised its position in Pfizer Inc. (NYSE:PFE) by 1.4% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 184,709 shares of the biopharmaceutical company’s stock after acquiring an additional 2,514 shares during the period. Bfsg LLC’s holdings in Pfizer were worth $4,681,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in PFE. Norges Bank purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $2,328,986,000. Charles Schwab Investment Management Inc. boosted its position in shares of Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after buying an additional 25,315,159 shares during the last quarter. Starboard Value LP purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $407,730,000. Raymond James Financial Inc. purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $274,694,000. Finally, Assenagon Asset Management S.A. boosted its position in shares of Pfizer by 307.5% during the first quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company’s stock valued at $254,574,000 after buying an additional 7,581,030 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group boosted their price objective on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Citigroup reissued a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Stock Down 0.6%

Shares of NYSE PFE opened at $24.40 on Tuesday. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business’s fifty day moving average price is $23.11 and its 200-day moving average price is $24.93. The stock has a market capitalization of $138.71 billion, a PE ratio of 17.30, a P/E/G ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. During the same quarter in the prior year, the firm earned $0.82 EPS. The business’s revenue for the quarter was down 7.8% compared to the same quarter last year. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were paid a dividend of $0.43 per share. The ex-dividend date was Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.05%. Pfizer’s payout ratio is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.